San Diego Stock Exchange

SEARCH SAN DIEGO STOCKS:

Symbol

AMYLIN PHARMACEUTICALS INC

Symbol	Name	Close	Change		Volume	Dayhigh	Daylow
AMLN	Amylin Pharma	21.75	0.23	+ 1.07%	1115464.00	21.80	21.19

Exchange	Earningspershare	52-Week High	52-Week Low
NASDAQ N-Mkt	-1.32	24.21	11.01

SourceBook Information

Amylin Pharmaceuticals Inc. is listed in:

• Biomed & Biotech Firms -
• Biomed & Biotech Firms - Publicly Traded -
• Highest Paid CEOs of BIO Tech Companies -
• Local Publicly Traded Companies -

Contact Information

Company Name

Amylin Pharmaceuticals Inc.

Executives

Daniel M. Bradbury, President/CEO

Mark G. Foletta, Sr. VP, Financial/CFO

Address

9360 Towne Centre Drive

San Diego, CA 92121

Phone

(858) 552-2200

Fax

(858) 552-2212

E-mail

ir@amylin.com

Web Page

www.amylin.com

Business Information

Parent Company

n/a

SIC Code

3841

Headquarters

San Diego, CA

Local Mailing Address

9360 Towne Centre Drive, Suite 110 San Diego, CA 92131

Year Established

1987

Year Established in San Diego

1987

Publicly Traded?

Yes

Ticker Symbol

AMLN

Total Number of Employees

1,150

Number of Local Employees

535

Number of Offices Local

n/a

Gross Revenue 2003 Year End

wnd

Business Description

Amylin is dedicated to improving lives through the discovery, development and commercialization of innovative medicines for the treatment of diabetes, obesity and cardiovascular disease.

Gross Revenue 2002 Year End

wnd

Business Services

Amylin is dedicated to improving lives through the discovery, development and commercialization of innovative medicines for the treatment of diabetes, obesity and cardiovascular disease. In the spring of 2005, Amylin received DFA approval for SYMLIN and BYETTA, two-first in class therapies to address teh epidemic of diabetes. SYMLIN for insulin dependent diabetics, and BYETTA, for type 2 diabetics unable to achieve glycemic control with metformin and/or sulfonlurea, address a significant portion of the continuum of diabetes care.

Industries of Interest

Biotechnology & drugs

Market Capitalization

$2,402,857,000

Gross Revenue 2000

wnd

Gross Revenue 2000 Year End

wnd

Gross Revenue 2001

wnd

Gross Revenue 2001 Year End

wnd

Gross Revenue 2002

wnd

Gross Revenue 2003

$44,600,000

Gross Revenue 2004

wnd

Gross Revenue 2005 YTD, Local

wnd

Gross Revenue 2007

n/a

Gross Revenue 2009

n/a

Gross Revenue 2010

n/a

Manufacturer

No

Fields of Research

Developing innovative medicines to beat metabolic diseases

Major Products

Smylin, Exentide, Exenatide LAR, AC2592 (GLP-1), AC3056, AC 162352 (PYY[2-26])

Major Investors

Capital Research & Management, Wellington Management, Farallon Capital Management Partners, Fidelity Management & Research, Deerfield Management Co.

Number of Products Approved For Sale

2

Patents

n/a

Number of Products In Development

5

Strategic Alliances

Eli Lilly, Alkermes Inc., Aventis.

Services Offered

n/a

Chief Executive Officer

Daniel Bradbury

Date CEO Began

2003

Total Annual CEO Compensation (salary & bonuses)

$1,396,000

CEO Salary

$925,000

CEO Bonuses

$471,000

Gross Revenue 2006

n/a

Sales for 2006

n/a

Gross Revenue 2008

n/a

Mission Statement

n/a